In terms of tumor characteristics, the HoR(+)/HER2(–) group was associated with lower grade (for grade 1: 28.8 vs. 5.8, 1.4, and 1.4%), smaller tumor sizes (for size ≤ 2 cm: 68.4 vs. 51.6, 45.7, and 44.9%), fewer positive lymph nodes (for positive nodes: 28.6 vs. 39.1, 43.4, and 34.3%), and a lower chemotherapy proportion (31.1 vs. 74.7, 78.6, and 77.2%). The gene discussed is ERBB2; the disease is neoplasm.